Table 4 Standard incidence ratios (SIR) and 95% confidence intervals (CI) for a second malignancy by cancer site in men and women with a history of cutaneous squamous cell carcinoma (SCC), adjusted for age and calendar period
From: New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway
|  |  | Women (N = 10 9651) | Men (N = 13 7481) | ||
|---|---|---|---|---|---|
ICD-10 | Cancer site2 | O3 | SIR (95% CI) | O3 | SIR (95% CI) |
C00-144 | Mouth, pharynx | 38 | 3.03 (2.20,4.16) | 114 | 3.23 (2.69,3.87) |
C07-08 | Salivary glands | 11 | 6.69 (3.71,12.1) | 17 | 6.19 (3.85,9.95) |
C18 | Colon | 176 | 1.25 (1.08,1.45) | 197 | 1.09 (0.95,1.25) |
C19-21 | Rectum | 45 | 0.86 (0.64,1.14) | 96 | 0.98 (0.80,1.20) |
C25 | Pancreas | 45 | 1.03 (0.77,1.38) | 82 | 1.39 (1.12,1.73) |
C33,34,38 | Lung | 82 | 1.46 (1.17,1.81) | 303 | 1.49 (1.32,1.66) |
C50 | Breast | 204 | 1.15 (1.00,1.32) | - | - |
C50-58 | Female organs | 320 | 1.11 (0.99,1.24) | - | - |
C61 | Prostate | - | - | 650 | 1.14 (1.06,1.23) |
C64-68 | Urinary organs | 42 | 0.69 (0.51,0.94) | 222 | 1.08 (0.94,1.23) |
C70-72 | CNS5 | 17 | 0.65 (0.40,1.04) | 32 | 1.10 (0.78,1.56) |
C73 | Thyroid | 12 | 7.30 (4.15,12.8) | 3 | 0.60 (0.19,1.85) |
C81-85 | Lymphoma | 64 | 2.14 (1.67,2.74) | 113 | 2.41 (2.00,2.90) |
C91-95 | Leukemia | 65 | 1.33 (1.04,1.69) | 150 | 1.70 (1.45,1.99) |
C00-966 | Other sites | 183 | 1.13 (0.98,1.31) | 371 | 1.37 (1.23,1.51) |
C43 | CMM | 95 | 3.09 (2.52,3.78) | 122 | 2.76 (2.31,3.29) |
C44 | SCC | 715 | 9.88 (9.18,10,6) | 1249 | 10.1 (9.51,10.6) |
C00-96 | All sites | 1898 | 1.89 (1.81,1.98) | 3725 | 1.91 (1.84,1.96) |
C00-967 | All, exc. skin | 1088 | 1.22 (1.15,1.30) | 2354 | 1.33 (1.28,1.39) |
C00-968 | All, exc. SCC | 1183 | 1.23 (1.16,1.30) | 2476 | 1.31 (1.25,1.36) |